

Specimen ID: [REDACTED]
Control ID: 30097438892

Acct #: [REDACTED]

Phone: [REDACTED]

Rte: 00

PETERSON, MIKHAILA
[REDACTED]
[REDACTED]
[REDACTED]

Specialty Health
330 E Liberty Ste 100
RENO NV 89501



Patient Details

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Specimen Details

Date collected: 12/21/2018 1118 Local
Date received: 12/21/2018
Date entered: 12/21/2018
Date reported: 12/24/2018 1305 ET

Physician Details

Ordering: S HALL
Referring:
ID:
NPI: [REDACTED]

General Comments & Additional Information

Total Volume: Not Provided

Fasting: Yes

Ordered Items

NMR LipoProf+Graph; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Hemoglobin A1c; TSH; Vitamin D, 25-Hydroxy; Lipoprotein (a); Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
NMR LipoProf+Graph					
LDL Particle Number					01
LDL-P	684		nmol/L	<1000	01
		Low		< 1000	
		Moderate		1000 - 1299	
		Borderline-High		1300 - 1599	
		High		1600 - 2000	
		Very High		> 2000	
Lipids					01
LDL-C	67		mg/dL	0 - 99	
		Optimal		< 100	
		Above optimal		100 - 129	
		Borderline		130 - 159	
		High		160 - 189	
		Very high		> 189	
Comment:					01
LDL-C is inaccurate if patient is non-fasting.					
HDL-C	58		mg/dL	>39	01
Triglycerides	41		mg/dL	0 - 149	01
Cholesterol, Total	133		mg/dL	100 - 199	01
LDL and HDL Particles					01
HDL-P (Total)	40.0		umol/L	>=30.5	01
Small LDL-P	372		nmol/L	<=527	01
LDL Size	20.2	Low	nm	>20.5	01

**** INTERPRETATIVE INFORMATION****

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES	Percentile in Reference Population				
	High	75th	50th	25th	Low
HDL-P (total)	>34.9	34.9	30.5	26.7	<26.7
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
LDL Size	<-Large (Pattern A)->		<-Small (Pattern B)->		

Patient: PETERSON, MIKHAILA
 DOB: ██████████

Patient ID: ██████████

Control ID: 30097438892

 Specimen ID: ██████████
 Date collected: 12/21/2018 1118 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
	23.0	20.6	20.5	19.0	

 Comment: 01

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established.

 Insulin Resistance Score 01

 LP-IR Score 27 <=45 01
INSULIN RESISTANCE MARKER

<--Insulin Sensitive Insulin Resistant-->

Percentile in Reference Population

Insulin Resistance Score

LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63

 Comment: 01

LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score listed above has not been cleared by the US Food and Drug Administration.

 NMR PDF Image 01
CBC With Differential/Platelet

WBC	5.2	x10E3/uL	3.4 - 10.8	02
RBC	4.61	x10E6/uL	3.77 - 5.28	02
Hemoglobin	13.6	g/dL	11.1 - 15.9	02
Hematocrit	41.9	%	34.0 - 46.6	02
MCV	91	fL	79 - 97	02
MCH	29.5	pg	26.6 - 33.0	02
MCHC	32.5	g/dL	31.5 - 35.7	02
RDW	15.1	%	12.3 - 15.4	02
Platelets	198	x10E3/uL	150 - 379	02
Neutrophils	62	%	Not Estab.	02
Lymphs	29	%	Not Estab.	02
Monocytes	8	%	Not Estab.	02
Eos	1	%	Not Estab.	02
Basos	0	%	Not Estab.	02
Neutrophils (Absolute)	3.2	x10E3/uL	1.4 - 7.0	02
Lymphs (Absolute)	1.5	x10E3/uL	0.7 - 3.1	02
Monocytes (Absolute)	0.4	x10E3/uL	0.1 - 0.9	02
Eos (Absolute)	0.1	x10E3/uL	0.0 - 0.4	02
Baso (Absolute)	0.0	x10E3/uL	0.0 - 0.2	02

Patient: PETERSON, MIKHAILA

DOB: ██████████

Patient ID: ██████████

Control ID: 30097438892

Specimen ID: ██████████

Date collected: 12/21/2018 1118 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Immature Granulocytes	0		%	Not Estab.	02
Immature Grans (Abs)	0.0		x10E3/uL	0.0 - 0.1	02
Comp. Metabolic Panel (14)					
Glucose	93		mg/dL	65 - 99	02
BUN	26	High	mg/dL	6 - 20	02
Creatinine	0.64		mg/dL	0.57 - 1.00	02
eGFR If NonAfricn Am	124		mL/min/1.73	>59	
eGFR If Africn Am	142		mL/min/1.73	>59	
BUN/Creatinine Ratio	41	High		9 - 23	
Sodium	137		mmol/L	134 - 144	02
Potassium	4.2		mmol/L	3.5 - 5.2	02
Chloride	98		mmol/L	96 - 106	02
Carbon Dioxide, Total	24		mmol/L	20 - 29	02
Calcium	9.0		mg/dL	8.7 - 10.2	02
Protein, Total	7.1		g/dL	6.0 - 8.5	02
Albumin	4.2		g/dL	3.5 - 5.5	02
Globulin, Total	2.9		g/dL	1.5 - 4.5	
A/G Ratio	1.4			1.2 - 2.2	
Bilirubin, Total	0.3		mg/dL	0.0 - 1.2	02
Alkaline Phosphatase	68		IU/L	39 - 117	02
AST (SGOT)	15		IU/L	0 - 40	02
ALT (SGPT)	20		IU/L	0 - 32	02
Hemoglobin A1c					
Hemoglobin A1c	5.2		%	4.8 - 5.6	02
Please Note:					
Prediabetes: 5.7 - 6.4					
Diabetes: >6.4					
Glycemic control for adults with diabetes: <7.0					
TSH	3.330		uIU/mL	0.450 - 4.500	02
Vitamin D, 25-Hydroxy	28.7	Low	ng/mL	30.0 - 100.0	02
<p>Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).</p> <p>1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.</p> <p>2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.</p>					

Patient: PETERSON, MIKHAILA
DOB: ██████████

Patient ID: ██████████

Control ID: 30097438892

Specimen ID: ██████████
Date collected: 12/21/2018 1118 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Lipoprotein (a)	6		nmol/L	<75	01
------------------------	---	--	--------	-----	----

Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
02	TA	LabCorp Tampa 5610 W LaSalle Street, Tampa, FL 33607-1770	Dir: Sean Farrier, MD

For inquiries, the physician may contact **Branch: 800-765-2755 Lab: 800-762-4344**

Specimen Number ██████████		Patient ID ██████		Account Number ██████████	Account Phone ██████████	Account Fax ██████████
Patient Last Name PETERSON		Patient First Name MIKHAILA		Account Address Specialty Health 330 E Liberty Ste 100 RENO, NV 89501		
Age ██	Date of Birth ██████████	Sex F	Fasting YES			
Control Number 30097438892		NPI ██████████				
Date Collected 12/21/2018	Date Entered 12/21/2018	Date and Time Reported 12/24/2018 12:58 AM ET		Physician ID & Name HALL, S		Page Number 1 of 2

NMR LipoProfile® test

Reference Range¹


	Percentile ¹	20th	50th	80th	95th	
nmol/L	Low	Moderate	Borderline High	High	Very High	
LDL-P (LDL Particle Number)	684	< 1000	1000 - 1299	1300 - 1599	1600 - 2000	> 2000

1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

Lipids

mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High	
LDL-C (calculated)	67	< 100	100 - 129	130 - 159	160 - 189	≥ 190
HDL-C	58	Triglycerides	41	Total Cholesterol	133	
Desirable ≥ 40		Desirable < 150		Desirable < 200		

Historical Reporting



Issued or Pending Patents



The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number

██████████

Specimen Number [REDACTED]		Patient ID [REDACTED]		Account Number [REDACTED]	Account Phone [REDACTED]	Account Fax [REDACTED]
Patient Last Name PETERSON		Patient First Name MIKHAILA		Account Address Specialty Health 330 E Liberty Ste 100 RENO, NV 89501		
Age [REDACTED]	Date of Birth [REDACTED]	Sex F	Fasting YES			
Control Number [REDACTED]		NPI [REDACTED]				
Date Collected 12/21/2018	Date Entered 12/21/2018	Date and Time Reported 12/24/2018 12:58 AM ET		Physician ID & Name HALL, S		Page Number 2 of 2

PARTICLE CONCENTRATION AND SIZE



Clinician Notes

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.